GlassScriptPhysician profile
Ashok K Joshi
NPI 1679568331
$12,284.85
in general payments reported to CMS, 2019-2025
48 companies · $2,368 in 2025
The $2,368 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $1,230 · 2021: $1,491 · 2022: $1,425 · 2023: $1,605 · 2024: $2,030 · 2025: $2,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,003.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,155.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,368.89 | 2019-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $1,088.74 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $813.63 | 2022-2025 | |
| Lilly USA, LLC | $770.21 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $715.75 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Abbvie INC. | $582.81 | 2021-2024 | |
| Glaxosmithkline, LLC. | $552.25 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.03 | 2019-2025 | Jardiance, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $432.21 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $392.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $351.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $330.98 | 2022-2025 | Rexulti, Jynarque |
| Novartis Pharmaceuticals Corporation | $240.72 | 2019-2023 | |
| Amarin Pharma, INC. | $213.33 | 2020-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.